Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloStim in relapsed/refractory hematological malignancy
NCT00558675Phase 2Completed
- Sponsor
- Mirror Biologics, Inc.
- Start
- Dec 2010
- Primary completion
- Dec 2012
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allostim in hematologic malignancy, sponsored by Mirror Biologics, Inc.. Started Dec 2010; status: completed.
02
Drugs
allostim
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00558675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00558675.